Use of biologics and other novel therapies for the treatment of systemic sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of biologics and other novel therapies for the treatment of systemic sclerosis

Published:2016-12-12 Issue:5 Volume:13 Page:469-482
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Bruni Cosimo¹,Praino Emanuela¹²,Allanore Yannick³,Distler Oliver⁴,Gabrielli Armando⁵,Iannone Florenzo²,Matucci-Cerinic Marco¹

Affiliation:

1. Department of Experimental and Clinical Medicine, Division of Rheumatology AOUC, University of Firenze, Firenze, Italy

2. Interdisciplinary Dept of Medicine, division of Rheumatology, University of Bari, Bari, Italy

3. Department of Rheumatology A and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France

4. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

5. Department Of Clinical and Molecular Sciences, Clinica Medica, University ‘Politecnica delle Marche’, Ancona, Italy

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2017.1263153

Reference140 articles.

1. Systemic sclerosis: a prototypic multisystem fibrotic disorder

2. Immunosuppression for interstitial lung disease in systemic sclerosis

3. Clinical trials in systemic sclerosis: lessons learned and outcomes

4. Update of EULAR recommendations for the treatment of systemic sclerosis

5. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature;International Journal of Rheumatic Diseases;2022-05-10

2. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review;Therapeutic Advances in Musculoskeletal Disease;2022-01

3. Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies;Frontiers in Medicine;2021-12-22

4. Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases;European Journal of Rheumatology;2021-11-22

5. French recommendations for the management of systemic sclerosis;Orphanet Journal of Rare Diseases;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3